Financial Report

Statement of financial position of PolyPeptide Group AG

As at 31 December

Assets, kCHF

Note

2023

2022

 

 

 

 

Current assets

 

 

 

Cash and cash equivalents

1

280

10,061

Other receivables from related parties

 

313

Other receivables from group companies

 

17,799

14,359

Accrued income and prepaid expenses

 

683

799

Total current assets

 

18,762

25,532

 

 

 

 

Non-current assets

 

 

 

Receivables from group companies

 

222,137

137,744

Financial assets

3

5,434

2,463

Investments

2

525,300

759,300

Tangible assets

 

683

779

Total non-current assets

 

753,554

900,286

 

 

 

 

Total assets

 

772,316

925,818

Statement of financial position of PolyPeptide Group AG (continued)

As at 31 December

Liabilities, kCHF

Note

2023

2022

 

 

 

 

Current liabilities

 

 

 

Other liabilities due to third parties

 

1,471

644

Other liabilities due to related parties

 

14

Interest-bearing liabilities due to shareholder

 

37,812

Accrued expenses and deferred income

 

134

80

Total short-term liabilities

 

39,417

738

 

 

 

 

Non-current liabilities

 

 

 

Interest-bearing liabilities due to third parties

 

46,301

Liabilities due to group companies

 

2,284

Total long-term liabilities

 

46,301

2,284

 

 

 

 

Shareholders' equity

 

 

 

Share capital

4

331

331

Statutory capital reserves

 

 

 

Reserves from capital contribution

5

2,104,803

2,104,803

Other capital reserves

 

4,949

4,949

Treasury shares

6

-10,943

-14,052

Net loss brought forward

 

-1,173,235

-9,604

Net loss for the year

 

-239,307

-1,163,631

Total shareholders' equity

 

686,598

922,796

 

 

 

 

Total liabilities and shareholders' equity

 

772,316

925,818